NCT07311941 Rapid Escalation of LipiD Lowering Therapy to Reduce RecUrrent Cardiovascular Event
| NCT ID | NCT07311941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese University of Hong Kong |
| Condition | Hyperlipidemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2024-12-30 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2024-12-30 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Hyperlipidaemia especially elevation of low-density lipoprotein cholesterol (LDL-C) is known to be the main contributor to the development of atherosclerotic cardiovascular disease (ASCVD). Lowering LDL-C have been shown to reduce the risk of ASCVD2,3. Both the American Heart Association (AHA) and the European Society of Cardiology (ESC) advocated aggressive LDL-C target with statin being the first-line lipid-lowering therapy (LLT). However, a significant portion of patients did not attain their LDL-C goal in our locality. Statin no adherence, low uptake of adjuvant non-statin LLT, and therapeutic inertia are few potential causes for not achieving the LDL-C target. ESC recommends repeating blood test in 6-8 weeks after addition or alternation of LLT, but this recommendation was not routinely followed in current local practice due to resources constrain. This registry therefore aims to investigate the strategy of frequent monitoring of LDL-C and titration of LLT in achieving LDL-C treatment target at a dedicated specialist clinic.
Eligibility Criteria
Inclusion Criteria: * Age \>18 * (Cohort 1) Diagnosis of acute coronary syndrome due to atherosclerotic coronary artery disease * (Cohort 2) Diagnosis of chronic coronary syndrome due to atherosclerotic coronary artery disease Exclusion Criteria: * Inability to provide valid consent by the patient or his legal guardian * Diagnosis of ACS due to other causes than atherosclerotic coronary artery disease. * Psychiatric or severe neurological disorder, cirrhosis, or active malignancy leading to a life expectancy \< 6 months.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07311941 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hyperlipidemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07311941 currently recruiting?
Yes, NCT07311941 is actively recruiting participants. Contact the research team at xjldaniel@gmail.com for enrollment information.
Where is the NCT07311941 trial being conducted?
This trial is being conducted at Shatin, Hong Kong.
Who is sponsoring the NCT07311941 clinical trial?
NCT07311941 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 1,000 participants.